SCHEMBL2909515

SCHEMBL2909515

CC(=O)OCCOc1ccc(-c2cccc(C=O)c2C)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 3/20 0.39
PDE3A Q14432 3/20 0.39
P2RY12 Q9H244 3/20 0.39
APP P05067 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PPARG P37231 3/20 0.36
PPARD Q03181 2/20 0.36
PPARA Q07869 2/20 0.36
PTPN11 Q06124 1/20 0.36
FFAR4 Q5NUL3 1/20 0.35
S1PR1 P21453 1/20 0.35
PDCD1 Q15116 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
FFAR1 O14842 1/20 0.35
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10203729 0.87 FFAR1 (0.35) PDE3BPDE3AP2RY12APPPDCD1
SCHEMBL2913115 0.85 ALDH1A1 (0.40) TDP1PDCD1CD274NPC1LMNA
SCHEMBL2020160 0.84 FFAR4 (0.35) TDP1L3MBTL1PPARGPPARDPPARA
SCHEMBL12578349 0.82 FFAR1 (0.44) FFAR4PDCD1CD274FFAR1MTNR1A
SCHEMBL13117620 0.82 ALDH1A1 (0.47) TDP1PPARGPPARDPPARAPDCD1
SCHEMBL12578473 0.81 FFAR1 (0.39) PPARGPPARDPPARAPTPN11FFAR4
SCHEMBL13117607 0.81 SMN1; SMN2 (0.37) TDP1L3MBTL1PPARDPDCD1CD274
SCHEMBL13117618 0.80 ALDH1A1 (0.40) TDP1PDCD1CD274NPC1LMNA
SCHEMBL13213451 0.80 PPARD (0.37) TDP1PPARGPPARDPPARAPTPN11
SCHEMBL13117494 0.80 ERN1 (0.40) PDCD1CD274SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 EP disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND GPR119, GLP1R, GPR4 PDE3B 1184/4885PDE3A 1469/4885P2RY12 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.